Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X:
“Learning about policy at the OneOncology Annual Conference.
I know very little about this area, and I’m glad we have thoughtful leaders working on it.
Policy shapes what reaches our patients in community practice as much as the trial data we talk about all day.
Worth an afternoon to listen.”
Katy Beckermann’s contribution to cancer care
- As Medical Director of Genitourinary Research at Tennessee Oncology, Beckermann leads clinical research in kidney, bladder, prostate, and testicular cancers, expanding opportunities for community patients to access emerging treatments locally.
- Her team has more than a dozen clinical trials open in kidney, bladder, and prostate cancer, bringing investigational treatment opportunities closer to patients receiving community-based oncology care.
- She has contributed to national cancer-treatment guidance, including ASCO recommendations for metastatic castration-resistant prostate cancer, helping translate clinical evidence into practical recommendations for oncology care across treatment settings.
- At the 2026 OneOncology Annual Conference, Beckermann joined discussions on how policy shapes access to clinical research and treatments for patients receiving community-based cancer care and influences practice nationwide.
You may also be interested in:
Katy Beckermann: Panel Discussion on Multidisciplinary Collaboration in Bladder Cancer Care
Katy Beckermann: OneOncology Annual Conference Expands Its Focus on Multidisciplinary GU Cancer Care